Reneo Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except share and per share data)
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Operating expenses: | ||
| Research and development | $56,613 | $37,705 |
| General and administrative | 26,440 | 16,143 |
| Total operating expenses | 83,053 | 53,848 |
| Loss from operations | (83,053) | (53,848) |
| Other income | 5,665 | 1,893 |
| Net loss | (77,388) | (51,955) |
| Unrealized gain (loss) on short-term investments | 51 | (77) |
| Comprehensive loss | $(77,337) | $(52,032) |
| Net loss per share attributable to common stockholders, basic and diluted | $(2.52) | $(2.12) |
| Weighted-average shares used in computing net loss per share, basic and diluted | 30,676,455 | 24,496,425 |
Consolidated Statements of Changes in Stockholders’ Equity
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.